Clinicopathological and immunological characterization of RNA m6A methylation regulators in ovarian cancer

Background N6‐methyladenosine (m6A) modification is one of the critical gene regulatory mechanisms implicated in cancer biology. However, the roles of m6A regulators in ovarian cancer are still poorly understood. Methods We integrated multiple databases including Gene Expression Omnibus (GEO), ROC P...

Full description

Saved in:
Bibliographic Details
Published inMolecular genetics & genomic medicine Vol. 9; no. 1
Main Authors Wang, Qingying, Zhang, Qinyi, Li, Qingxian, Zhang, Jing, Zhang, Jiawen
Format Journal Article
LanguageEnglish
Published Bognor Regis John Wiley & Sons, Inc 01.01.2021
John Wiley and Sons Inc
Wiley
Subjects
Bioinformatics
Cancer
Cancer therapies
Chemotherapy
Datasets
Dendritic cells
Gene expression
immune infiltration
Immune system
Immunology
Lymphocytes
m6A regulators
Malignancy
Medical prognosis
Metastases
Mutation
N6-methyladenosine
Neutrophils
Original
Ovarian cancer
Paclitaxel
Plotters
Regulatory mechanisms (biology)
Software
survival
Tumorigenesis
Tumors
Online AccessGet full text

Cover

More Information
Summary:Background N6‐methyladenosine (m6A) modification is one of the critical gene regulatory mechanisms implicated in cancer biology. However, the roles of m6A regulators in ovarian cancer are still poorly understood. Methods We integrated multiple databases including Gene Expression Omnibus (GEO), ROC Plotter, Kaplan‐Meier Plotter, and Tumor Immune Estimation Resource (TIMER) to explore clinicopathological significance of m6A regulators in ovarian cancer. Results We showed that alterations in the expression of m6A regulators were related to the malignancy and poor prognosis of ovarian cancer. We found decreased YTHDC1 and increased RBM15 expressions were associated with ovarian cancer cell metastases and HNRNPC was a predictor of paclitaxel resistance. Moreover, dysregulated m6A regulators were enriched in the activation of cancer‐related pathways. Our results further demonstrated that the level of immune cell infiltration and the expression of various immune gene markers were closely associated with the expressions of specific m6A regulators (RBM15B, ZC3H13, YTHDF1, and IGF2BP1). Conclusions Our study establishes a new prognostic profile of ovarian cancer patients based on m6A regulators, and highlights the potential roles of m6A regulators in ovarian cancer development. m6A regulators play important roles in ovarian cancer cell biology.
Bibliography:Qingying Wang and Qinyi Zhang contributed equally.
ISSN:2324-9269
2324-9269
DOI:10.1002/mgg3.1547